Multiple sclerosis (MS) is a chronic disease of the central nervous system. About 400,000 Americans have MS,although this may be an underestimate. The disease affects about three times as many women as men and some patient groups, such as African Americans, experience a more rapid and severe clinical course. Our review looks at two types of multiple sclerosis: relapsing-remitting (RRMS) and primary-progressive (PPMS). RRMS affects about 85-90% of patients with MS, while PPMS affects about 10-15%. Patients with RRMS, experience periodic relapses in symptoms which may improve with treatment, while those with PPMS experience steadily worsening symptoms.

2017 Review: Relapsing-Remitting MS and Primary Progressive MS

Interventions of Interest:

Injectable Agents

  • Daclizumab (Zinbryta®, Biogen/AbbVie)
  • Glatiramer acetate (Copaxone®, Teva)
  • Glatiramer acetate (Glatopa®, Sandoz (Novartis))
  • Interferon beta-1a (Avonex®, Biogen)
  • Interferon beta-1b (Betaseron®, Bayer)
  • Interferon beta-1b (Extavia®, Novartis)
  • Interferon beta-1a (Rebif®, EMD Serono)
  • Peginterferon beta-1a (Plegridy®, Biogen)

Oral Agents

  • Dimethyl fumarate (Tecfidera®, Biogen)
  • Fingolimod (Gilenya®, Novartis)
  • Teriflunomide (Aubagio®, Sanofi-Genzyme)

Infused Agents

  • Alemtuzumab (Lemtrada®, Sanofi-Genzyme)
  • Natalizumab (Tysabri®, Biogen)
  • Ocrelizumab (Ocrevus®, Roche/Genentech)
  • Rituximab (Rituxan®, Roche/Genentech)

For questions, contact info@icer.org

View the Key Stakeholders List.


Final Documents

Below you will find the final documents from the assessment review process: